Conclusion
As evidenced by the current literature, the PIG-A mutation test
is a promising tool for human biomonitoring and disease. With further
technological development, test battery development and international
collaboration, we expect this simple, high-throughput assay to advise us
on both harmful and beneficial exposures to genotoxins and
chemo-preventative agents. This will ultimately lead to improved
lifestyle choices, reduced occupational hazards and even earlier
diagnosis of high-risk cancer patients and other cancer associated
inflammatory diseases such as IBD.